Médecine

Paramédical

Autres domaines


Suscribirse

Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools - 18/06/20

Doi : 10.1016/j.biopha.2020.110316 
Qi Kong a, , Yue Wu a, Yu Gu a, Qi Lv a, Feifei Qi a, Shuran Gong a, Xiuping Chen b,
a Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China 
b Medical College, Qingdao University, Qingdao 266071, PR China 

Corresponding authors.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

Pudilan (PDL) was proven to be useful in the treatment of 2019 novel coronavirus disease (COVID-19).
Pudilan (PDL) might inhibit the cytokine storm in 2019 novel coronavirus disease (COVID-19) by affecting Interleukin-1β (IL-1β) and related proteins.
Pudilan (PDL) might prevent the entry of SARS-CoV-2 into cells by affecting angiotensin I converting enzyme 2 (ACE2).
Pudilan (PDL) might also moderate human immune system with traditional Chinese medicine theory.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified.

Methods

We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform.

Results

PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate.

Conclusion

PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.

El texto completo de este artículo está disponible en PDF.

Abbreviations : ACE2, ARDS, BXTM, COVID-19, LHQW, HSZF, PDL, SARS-CoV-2, SFJD, TCM

Keywords : SARS-CoV-2 infection, COVID-19, Traditional Chinese herbs, Targeted therapy, Network pharmacology


Esquema


© 2020  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 128

Artículo 110316- août 2020 Regresar al número
Artículo precedente Artículo precedente
  • Docosahexaenoic acid protects against palmitate-induced mitochondrial dysfunction in diabetic cardiomyopathy
  • Ting Gui, Yunlun Li, Shijun Zhang, Nan Zhang, Ying Sun, Fengzhen Liu, Qingfa Chen, Zhibo Gai
| Artículo siguiente Artículo siguiente
  • Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells
  • Naoyuki Tange, Fumihiko Hayakawa, Takahiko Yasuda, Koya Odaira, Hideyuki Yamamoto, Daiki Hirano, Toshiyasu Sakai, Seitaro Terakura, Shinobu Tsuzuki, Hitoshi Kiyoi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.